Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043808 · ClinicalTrials.gov registry record
The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 25,586
- Enrollment target
NCT02043808: Completed study, sponsored by Boehringer Ingelheim.
NCT02043808 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 25,586 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02043808 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 25,586 participants
- Enrollment target
Study Summary
The objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with NVAF in the US DoD population.
Primary Outcome
Event rate of stroke (hemorrhagic, ischemic). Variables in the final propensity score model: age, gender index year, baseline CHADS(2) score (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Prior Stroke or transient ischemic attack (TIA) or Thromboembolism), baseline CHA(2)DS(2)-VASc score (Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, Stroke (doubled), Vascular disease, Age 65-74 years, Sex category), baseline HAS-BLED score (Hype
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,586 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-05 |
What the finished NCT02043808 record still lists
NCT02043808 is an observational study that tracks outcomes without assigning an intervention. Its 25,586 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02043808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02043808 about?
NCT02043808 is a clinical study titled "The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage". The objective is to assess the safety and effectiveness of new dabigatran and warfarin patients diagnosed with NVAF in the US DoD population.
What is the current status of trial NCT02043808?
This trial is currently completed. The enrollment target is 25,586 participants. The study started on 2014-01. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT02043808?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07300839 · 25,500 participants · Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
- NCT03175302 · 25,240 participants
PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing
- NCT04595201 · 25,000 participants
Clinical Follow-up of Pregnant Subjects Undergoing NIPT
- NCT04994015 · 25,000 participants
Parkinson's Foundation PD GENEration Genetic Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia